Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RCUS | US
-0.24
-1.67%
Healthcare
Biotechnology
31/03/2024
05/07/2024
14.12
13.87
14.35
13.61
Arcus Biosciences Inc. a clinical-stage biopharmaceutical company develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab an anti-TIGIT investigational monoclonal antibody which is in Phase 2 and Phase 3 clinical trial; and AB308 an investigational anti-TIGIT monoclonal antibody which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant a dual A2a/A2b adenosine receptor antagonist which is in Phase 2 clinical trial; Quemliclustat a small-molecule CD73 inhibitor which is Phase 1b and Phase 2 clinical trial; Zimberelimab an anti-PD-1 antibody which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521 an oral and small-molecule inhibitor of HIF-2a which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition the company's preclinical pipeline products include AB598 a CD39 antibody; and AB801 a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences Inc. was incorporated in 2015 and is headquartered in Hayward California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
32.9%1 month
46.1%3 months
46.7%6 months
59.7%-
-
3.26
0.02
0.01
-2.61
6.48
-
-241.00M
1.28B
1.28B
-
2.76
-
480.00
-35.35
11.35
18.06
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.21
Range1M
3.57
Range3M
4.46
Rel. volume
0.93
Price X volume
12.31M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MannKind Corporation | MNKD | Biotechnology | 5.13 | 1.40B | 1.99% | 130.50 | -162.73% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 20.21 | 1.39B | 3.22% | n/a | 12.31% |
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 19.36 | 1.37B | 1.36% | 143.62 | 2.81% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 34.87 | 1.36B | 9.28% | n/a | 1.27% |
Belite Bio Inc | BLTE | Biotechnology | 45.5 | 1.36B | -0.55% | n/a | 0.00% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 6.52 | 1.35B | 1.72% | n/a | -173.65% |
Verona Pharma plc | VRNA | Biotechnology | 16.11 | 1.31B | 2.55% | n/a | 22.79% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 61.44 | 1.29B | 1.02% | 39.55 | 68.66% |
Ardelyx Inc | ARDX | Biotechnology | 5.29 | 1.24B | -0.56% | n/a | 69.54% |
ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 10.49 | 1.21B | 9.27% | n/a | 91.91% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.45 | 1.31B | -0.37% | n/a | 20.15% |
REV Group Inc | REVG | Recreational Vehicles | 24.74 | 1.28B | -2.06% | 5.86 | 66.74% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.36 | 1.14B | 1.60% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.73 | 799.13M | -2.42% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.61 | -2.43 | Cheaper |
Ent. to Revenue | 6.48 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 3.26 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 46.69 | 76.52 | Lower Risk |
Debt to Equity | 0.02 | 0.51 | Cheaper |
Debt to Assets | 0.01 | 0.24 | Cheaper |
Market Cap | 1.28B | 3.77B | Emerging |